Systematic comparison of the statistical operating characteristics of various Phase I oncology designs

Revathi Ananthakrishnan, Stephanie Green, Mark Chang, Gheorghe Doros, Joseph M. Massaro, Michael P. LaValley

Type: Article

Publication Date: 2016-11-24

Citations: 18

DOI: https://doi.org/10.1016/j.conctc.2016.11.006

View Publication

Locations

PubMed Central - View
Contemporary Clinical Trials Communications - View
Europe PMC (PubMed Central) - View - PDF
DOAJ (DOAJ: Directory of Open Access Journals) - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	ATLCEP: A New Integrated Design that Encompasses the Safety and Efficacy Objectives of Phase I/II Trials	2017	Revathi Ananthakrishnan Stephanie Green Mark P. J. L. Chang Gheorghe Doros Joseph M. Massaro Daniel Li Michael P. LaValley
+ PDF Chat	A hybrid design for dose‐finding oncology clinical trials	2022	Jason J. Z. Liao Feng Zhou Heng Zhou Lilli Petruzzelli Kevin Hou Ekaterine Asatiani
+ PDF Chat	Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology	2024	Hao Sun Hsin‐Yu Lin Jieqi Tu Revathi Ananthakrishnan Eunhee Kim
+	Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2018	Heng Zhou Ying Yuan Lei Nie
+	Rule-Based Designs Considering Toxicity Alone	2019	Takashi Daimon Akihiro Hirakawa Shigeyuki Matsui
+	Data from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2023	Heng Zhou Ying Yuan Lei Nie
+	Data from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2023	Heng Zhou Ying Yuan Lei Nie
+	A Unified Decision Framework for Phase I Dose-Finding Designs	2021	Yunshan Duan Shijie Yuan Yuan Ji Peter P. Mueller
+	Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials	2022	Rong Liu Ying Yuan Suman Sen Yang Xin Qi Jiang Xiaoyun Li Chengxing Lu Mithat Gönen Hong Tian Heng Zhou
+	Introduction to Phase I Dose-Finding Clinical Trials	2023	Haitao Pan Ying Yuan
+	Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs	2018	Zhengjia Chen Youyun Zheng Zhibo Wang Michael Kutner Walter J. Curran Jeanne Kowalski
+ PDF Chat	Overview of model-assisted design for phase I dose-finding trials in oncology	2022	Koichi Hashizume Kentaro Takeda Hiroyuki Sato Akihiro Hirakawa Takashi Sozu
+ PDF Chat	The i3+3 design for phase I clinical trials.	2019	Yuan Ji Meizi Liu
+ PDF Chat	Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials	2017	Graham Wheeler Michael Sweeting Adrian Mander
+ PDF Chat	Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols	2021	Nolan A. Wages Bethany J. Horton Mark R. Conaway Gina R. Petroni
+	Model-Assisted Designs Considering Toxicity Alone	2019	Takashi Daimon Akihiro Hirakawa Shigeyuki Matsui
+ PDF Chat	A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials	2015	Graham Wheeler Michael Sweeting Adrian Mander
+	Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment	2022	Xin Wei Rong Liu
+	Phase I clinical trials in oncology: A review of the old and a look at the new.	2017	Bryan Fellman Kenneth R. Hess
+ PDF Chat	Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials	2014	Alexia Iasonos John O’Quigley

Works That Cite This (16)

Action	Title	Year	Authors
+ PDF Chat	A Bayesian adaptive design for cancer phase I trials using a flexible range of doses	2017	Mourad Tighiouart Galen Cook‐Wiens André Rogatko
+	R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials	2019	Wentian Guo Yuan Ji Daniel Li
+ PDF Chat	ATLCEP: A New Integrated Design that Encompasses the Safety and Efficacy Objectives of Phase I/II Trials	2017	Revathi Ananthakrishnan Stephanie Green Mark P. J. L. Chang Gheorghe Doros Joseph M. Massaro Daniel Li Michael P. LaValley
+ PDF Chat	Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols	2021	Nolan A. Wages Bethany J. Horton Mark R. Conaway Gina R. Petroni
+	Enhancement of Bayesian optimal interval design by accounting for overdose and underdose errors trade-offs	2023	Ryo Sadachi Hiroyuki Sato Takeo Fujiwara Akihiro Hirakawa
+ PDF Chat	Healthy volunteers in first‐in‐human oncology drug development for small molecules	2021	Begoña de las Heras Dalila Bouyoucef‐Cherchalli Lesley Reeve Andreas Reichl Debra Mandarino Stephen Flach Laura Vidal Emilie M.J. van Brummelen Neeltje Steeghs
+	Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials	2018	Revathi Ananthakrishnan Stephanie Green Daniel Li Michael P. LaValley
+	Two‐stage subgroup‐specific time‐to‐event (2S‐Sub‐TITE): An adaptive two‐stage time‐to‐toxicity design for subgroup‐specific dose finding in phase I oncology trials	2022	Alana McGovern Andrew G. Chapple Clement Ma
+ PDF Chat	Improving the performance of Bayesian logistic regression model with overdose control in oncology dose‐finding studies	2022	Hongtao Zhang Alan Y. Chiang Jixian Wang
+	Dose-Finding and Dose-Ranging Studies	2022	Mark R. Conaway Gina R. Petroni

Works Cited by This (30)

Action	Title	Year	Authors
+	Adaptive clinical trial designs in oncology.	2014	Yong Zang J. Jack Lee
+ PDF Chat	Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents	2012	Christophe Le Tourneau Hui Gan Albiruni R. Abdul Razak Xavier Paolettí
+	An evaluation of phase I clinical trial designs in the continuous dose–response setting	2001	Barry E. Storer
+ PDF Chat	Adaptive clinical trial designs for phase I cancer studies	2014	Oleksandr Sverdlov Weng Kee Wong Yevgen Ryeznik
+ PDF Chat	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan
+	Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study	2006	Xavier Paolettí Benoît Baron Patrick Schöffski P. Fumoleau Denis Lacombe Sandrine Marréaud Richard Sylvester
+	The continual reassessment method for dose-finding studies: a tutorial	2006	Elizabeth Garrett‐Mayer
+	Toxicity equivalence range design (TEQR): A practical Phase I design	2010	M. Suzette Blanchard Jeff Longmate
+	Adaptive Designs in Drug Development	2014	Mourad Tighiouart André Rogatko
+	Escalation, group andA +B designs for dose-finding trials	2005	Anastasia Ivanova